New Publication Alert — Check Out Our Latest Breakthrough!

We’re thrilled to announce the publication of our groundbreaking study: “Tumor‑restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer”, now available in Frontiers in Immunology: https://doi.org/10.3389/fimmu.2025.1628501

Discover how Evobodies, a first‑in‑class bispecific therapeutic antibody, selectively targets ovarian tumors by activating BTN3A only on FOLR1‑positive cancer cells. This induces localized immune responses and T‑cell proliferation while minimizing off‑target effects — showcasing strong potential for next‑generation solid tumor immunotherapy